STRO Sutro Biopharma, Inc. Stock Quote

STRO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	0.70%	Shs Outstand	45.91M	Perf Week	-5.95%
Market Cap	853.78M	Forward P/E	-	EPS next Y	-2.30	Insider Trans	-2.26%	Shs Float	40.72M	Perf Month	-9.31%
Income	-32.10M	PEG	-	EPS next Q	-0.48	Inst Own	98.40%	Short Float	9.07%	Perf Quarter	-26.82%
Sales	42.70M	P/S	19.99	EPS this Y	59.40%	Inst Trans	2.81%	Short Ratio	7.69	Perf Half Y	38.58%
Book/sh	6.69	P/B	2.88	EPS next Y	0.80%	ROA	-	Target Price	31.83	Perf Year	100.52%
Cash/sh	5.68	P/C	3.40	EPS next 5Y	-	ROE	-	52W Range	7.06 - 28.30	Perf YTD	-11.15%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-19.90%	52W High	-31.84%	Beta	-
Dividend %	-	Quick Ratio	11.70	Sales past 5Y	-	Gross Margin	-	52W Low	173.23%	ATR	1.34
Employees	191	Current Ratio	11.70	Sales Q/Q	104.20%	Oper. Margin	-	RSI (14)	42.59	Volatility	6.35% 6.62%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.53	Prev Close	18.52
Shortable	Yes	LT Debt/Eq	0.08	Earnings	Mar 18 BMO	Payout	-	Avg Volume	480.11K	Price	19.29
Recom	1.70	SMA20	-3.54%	SMA50	-10.40%	SMA200	10.08%	Volume	254,697	Change	4.16%

Dec-03-20

Initiated

Stifel

Buy

$25

Sep-02-20

Initiated

Jefferies

Buy

$21

Jul-16-20

Initiated

Wells Fargo

Overweight

$18

Jan-13-20

Initiated

SunTrust

Buy

$18

Oct-07-19

Initiated

BTIG Research

Buy

$19

Jul-18-19

Initiated

Deutsche Bank

Buy

$22

Apr-29-19

Initiated

H.C. Wainwright

Buy

$18

Oct-22-18

Initiated

Wedbush

Outperform

$20

Oct-22-18

Initiated

Piper Jaffray

Overweight

$23

Oct-22-18

Initiated

JMP Securities

Mkt Outperform

$28

May-07-21 08:25AM	Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones PR Newswire
Apr-20-21 07:00AM	Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer PR Newswire
Apr-19-21 04:47PM	Is STRO Stock A Buy or Sell? Insider Monkey -6.65%
Apr-15-21 07:00AM	Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck PR Newswire +7.18%
Apr-08-21 07:00AM	Sutro Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Mar-22-21 10:31AM	Have Insiders Been Buying Sutro Biopharma, Inc. (NASDAQ:STRO) Shares? Simply Wall St.
07:00AM	Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board PR Newswire
Mar-18-21 08:35AM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones PR Newswire
Mar-12-21 08:30AM	Why Sutro Biopharma (STRO) Might Surprise This Earnings Season Zacks
Mar-08-21 12:30PM	Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-23-21 07:00AM	Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference PR Newswire
Jan-21-21 07:00AM	Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer PR Newswire
Jan-05-21 07:00AM	Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire +6.08%
Dec-11-20 04:01PM	Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire
Dec-08-20 09:10PM	Sutro Biopharma Announces Pricing of $126.0 Million Public Offering PR Newswire
Dec-07-20 04:00PM	Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock PR Newswire
10:00AM	Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting PR Newswire
Dec-04-20 06:22PM	Why Sutro Biopharma Blasted 33% Higher on Friday Motley Fool +33.24%
12:59PM	Why BioCryst, Moderna And More Are Moving Today Benzinga
07:43AM	The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga
Dec-03-20 04:30PM	Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer PR Newswire
01:09PM	Why Sutro, Lumos And More Health Care Stocks Are Moving Today Benzinga
Dec-01-20 07:00AM	Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors PR Newswire
Nov-24-20 07:00AM	Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer PR Newswire +6.11%
Nov-18-20 07:00AM	Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations PR Newswire
Nov-09-20 09:49AM	Sutro Biopharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year Simply Wall St.
Nov-05-20 07:00AM	Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments PR Newswire
Nov-03-20 01:33PM	If You Had Bought Sutro Biopharma (NASDAQ:STRO) Stock A Year Ago, You Could Pocket A 27% Gain Today Simply Wall St.
Oct-12-20 12:10PM	Hedge Funds Are Dipping Their Toes Into Sutro Biopharma, Inc. (STRO) Insider Monkey
Sep-21-20 07:00AM	Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC PR Newswire -7.34%
Sep-10-20 07:20AM	The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial Benzinga -16.35%
Sep-09-20 04:01PM	Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting PR Newswire
Sep-04-20 07:27AM	Sutro Biopharma, Inc. (NASDAQ:STRO) Insiders Increased Their Holdings Simply Wall St.
Sep-03-20 04:27PM	Macy's, Carnival: 5 Big Stock Gainers for Thursday TheStreet.com +15.40%
07:55AM	The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax Benzinga
07:00AM	Sutro Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Sep-02-20 04:12PM	Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting PR Newswire +11.53%
10:22AM	Well Fargo Says These 2 Stocks Could Rally Over 70% From Current Levels TipRanks
Aug-25-20 07:00AM	Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors PR Newswire
Aug-11-20 07:00AM	Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing PR Newswire
Aug-10-20 05:00PM	Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Aug-06-20 12:15PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments PR Newswire
Aug-05-20 12:30PM	Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should Know Zacks
Jun-30-20 11:06PM	Were Hedge Funds Right About Souring On Sutro Biopharma, Inc. (STRO)? Insider Monkey
Jun-22-20 07:00AM	Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity PR Newswire
Jun-11-20 02:34PM	Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO) Business Wire -13.39%
Jun-09-20 07:00AM	Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020 PR Newswire
Jun-08-20 06:06PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO GlobeNewswire
01:25PM	Got $1,000? Buy These 4 Cancer Stocks Motley Fool
Jun-03-20 04:49PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO GlobeNewswire
May-27-20 08:46AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO GlobeNewswire
May-25-20 03:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO ACCESSWIRE
May-21-20 07:15AM	Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller PR Newswire -5.75%
07:00AM	Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD PR Newswire
May-14-20 04:01PM	Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire -7.39%
May-13-20 11:25AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO GlobeNewswire
May-12-20 04:45PM	STRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sutro Biopharma, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE -12.36%
May-11-20 11:55PM	Sutro Biopharma Announces Pricing of $85.3 Million Public Offering PR Newswire
04:15PM	Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments PR Newswire
Apr-27-20 12:01AM	Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer PR Newswire -16.47%
Apr-20-20 04:35PM	Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate PR Newswire
Apr-13-20 05:00PM	Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020 PR Newswire
11:01AM	Will Sutro Biopharma Continue to Surge Higher? Zacks
Mar-26-20 09:20AM	$110M injection powers up Peninsula vaccine maker but not for COVID-19 American City Business Journals +5.57%
07:00AM	SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia PR Newswire
Mar-16-20 08:35AM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates Zacks -39.31%
07:00AM	Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments PR Newswire
Mar-12-20 07:00AM	Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck PR Newswire
Mar-04-20 07:00AM	Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London PR Newswire +6.20%
Feb-06-20 01:13PM	Does Sutro Biopharma (NASDAQ:STRO) Have A Healthy Balance Sheet? Simply Wall St.
Feb-05-20 07:30AM	Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development PR Newswire
Jan-09-20 07:00AM	Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-08-20 09:26AM	Sutro Biopharma Appoints James Panek to Board of Directors PR Newswire
Dec-19-19 04:46PM	Do Hedge Funds Love Sutro Biopharma, Inc. (STRO)? Insider Monkey
Nov-19-19 07:00AM	Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference PR Newswire
Nov-08-19 10:57AM	Sutro Biopharma, Inc. (STRO): Hedge Funds Are Snapping Up Insider Monkey
07:00AM	Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments PR Newswire
Oct-30-19 01:59PM	Introducing Sutro Biopharma (NASDAQ:STRO), The Stock That Dropped 15% In The Last Year Simply Wall St.
Oct-29-19 07:32AM	The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
07:00AM	Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer PR Newswire
Oct-27-19 12:56PM	The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings Benzinga
Oct-16-19 04:35PM	Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference PR Newswire
Oct-08-19 07:00AM	Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors PR Newswire
Sep-04-19 07:00AM	Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference PR Newswire
Sep-03-19 10:32AM	Targeting flesh-eating, drug-resistant bacteria, Peninsula company grabs small grant for antibiotic American City Business Journals
Aug-14-19 06:15AM	Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments PR Newswire -6.96%
Aug-08-19 07:00AM	Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference PR Newswire
Jul-31-19 12:52PM	Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way? Simply Wall St.
Jul-04-19 04:08PM	Heres What Hedge Funds Think About Sutro Biopharma, Inc. (STRO) Insider Monkey
Jun-24-19 04:05PM	Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair PR Newswire
Jun-18-19 07:00AM	Sutro Biopharma to Present at the JMP Securities Life Sciences Conference PR Newswire +6.92%
Jun-15-19 06:00AM	Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress PR Newswire
May-16-19 09:02AM	Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress PR Newswire
May-15-19 07:00AM	Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments PR Newswire -7.73%
Apr-08-19 05:42PM	How free-flowing cash is accelerating small companies' cancer drug trials American City Business Journals
Apr-04-19 07:00AM	Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference PR Newswire
Apr-01-19 05:00AM	Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments PR Newswire

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NEWELL WILLIAM J	CEO	Jan 29	Option Exercise	0.00	13,750	0	192,410	Feb 01 05:56 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 29	Option Exercise	0.00	5,250	0	22,966	Feb 01 05:55 PM
Hallam Trevor	Chief Scientific Officer	Jan 29	Option Exercise	0.00	5,250	0	61,367	Feb 01 05:55 PM
FITZPATRICK LINDA A	Chief People & Comm. Officer	Jan 29	Option Exercise	0.00	8,250	0	23,866	Feb 01 05:54 PM
Shabbir Anik	Chief Technical Ops. Officer	Jan 29	Option Exercise	0.00	4,500	0	15,765	Feb 01 05:53 PM
ALBINI EDWARD C	CFO and Secretary	Jan 29	Option Exercise	0.00	5,250	0	16,326	Feb 01 05:48 PM
Hallam Trevor	Chief Scientific Officer	Jan 26	Option Exercise	4.36	2,393	10,433	58,510	Jan 27 05:04 PM
Petree Daniel H	Director	Jan 26	Option Exercise	4.36	4,132	18,016	7,988	Jan 27 05:05 PM
Hallam Trevor	Chief Scientific Officer	Jan 26	Sale	25.71	2,393	61,528	56,117	Jan 27 05:04 PM
FITZPATRICK LINDA A	Chief People & Comm. Officer	Jan 19	Option Exercise	4.36	1,652	7,203	15,616	Jan 20 05:21 PM
Hallam Trevor	Chief Scientific Officer	Jan 14	Option Exercise	4.36	19,405	84,606	56,117	Jan 15 06:10 PM
Hallam Trevor	Chief Scientific Officer	Dec 28	Option Exercise	4.36	2,393	10,433	39,105	Dec 29 05:00 PM
Hallam Trevor	Chief Scientific Officer	Dec 28	Sale	22.37	2,393	53,530	36,712	Dec 29 05:00 PM
Hallam Trevor	Chief Scientific Officer	Nov 27	Option Exercise	4.36	2,393	10,433	39,105	Nov 30 05:14 PM
Hallam Trevor	Chief Scientific Officer	Nov 27	Sale	17.01	2,393	40,713	36,712	Nov 30 05:14 PM
Hallam Trevor	Chief Scientific Officer	Nov 05	Option Exercise	4.36	16,751	73,034	53,463	Nov 06 05:08 PM
Hallam Trevor	Chief Scientific Officer	Nov 05	Sale	15.00	16,751	251,265	36,712	Nov 06 05:08 PM
Hallam Trevor	Chief Scientific Officer	Oct 05	Option Exercise	4.36	9,182	40,034	36,712	Oct 06 04:54 PM
Hallam Trevor	Chief Scientific Officer	Sep 28	Sale	10.26	975	10,007	27,530	Sep 28 05:55 PM
Hallam Trevor	Chief Scientific Officer	Sep 25	Option Exercise	0.00	17,906	0	30,886	Sep 28 05:55 PM
FITZPATRICK LINDA A	Chief People & Comm. Officer	Sep 25	Option Exercise	0.00	7,576	0	16,583	Sep 28 05:54 PM
ALBINI EDWARD C	CFO and Secretary	Sep 25	Option Exercise	0.00	7,174	0	13,556	Sep 28 05:52 PM
Shabbir Anik	Chief Technical Ops. Officer	Sep 25	Option Exercise	0.00	8,609	0	14,241	Sep 28 05:53 PM
NEWELL WILLIAM J	CEO	Sep 25	Option Exercise	0.00	25,252	0	191,879	Sep 28 05:57 PM
MOLINA ARTURO MD	Chief Medical Officer	Sep 25	Option Exercise	0.00	8,609	0	20,692	Sep 28 05:56 PM
Freund John Gordon	Director	Sep 18	Sale	12.00	400,000	4,800,000	560,053	Sep 22 04:56 PM
Freund John Gordon	Director	Sep 11	Sale	10.00	500,000	5,000,000	960,053	Sep 15 05:15 PM
Hallam Trevor	Chief Scientific Officer	Aug 26	Sale	9.04	975	8,818	16,790	Aug 27 05:04 PM
Freund John Gordon	Director	Aug 19	Sale	8.72	500,000	4,360,000	1,460,053	Aug 21 05:18 PM
Hallam Trevor	Chief Science Officer	Jul 27	Sale	8.06	975	7,858	17,765	Jul 28 05:08 PM
Hallam Trevor	Chief Science Officer	May 26	Sale	10.00	975	9,753	19,715	May 27 06:38 PM
NEWELL WILLIAM J	CEO	May 14	Buy	7.75	64,516	499,999	166,627	May 14 05:29 PM
MOLINA ARTURO MD	Chief Medical Officer	May 14	Buy	7.75	6,451	49,995	12,083	May 14 05:27 PM
FITZPATRICK LINDA A	Chief People & Comm. Officer	May 14	Buy	7.75	3,225	24,994	9,007	May 14 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience